Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The expansion includes a larger technical and service team and increased local procurement
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Subscribe To Our Newsletter & Stay Updated
